http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
Gilead Sciences Announces Second Quarter 2021 Dividend
-
Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India
-
Dispersion Holdings PLC Intention to Float on AQSE Growth Market
-
Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021
-
Gilead Sciences (GILD) Confirms U.S. FDA Granted Accelerated Approval to Trodelvy for Treatment of Metastatic Urothelial Cancer
-
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
-
Gilead Sciences (GILD) Announces FDA Approves Trodelvy, the First Treatment for Metastatic TNBC Shown to Improve PFS and OS
-
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
-
Gilead's (GILD) Kite Submits sBLA to FDA for Tecartus in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
-
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
-
Gilead Sciences Comments on the Passing of John C. Martin, PhD
-
Gilead Sciences (GILD) Appoints Flavius Martin, MD as Executive Vice President, Research
-
Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research
-
Gilead Sciences (GILD) Announces EMA Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
-
European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
-
Gilead Sciences (GILD), Novo Nordisk (NVO) Expand NASH Clinical Collaboration
-
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
-
Gilead (GILD), Merck (MRK) Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
-
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
-
Gilead Sciences (GILD) Lenacapavir Demonstrates Sustained Long-Acting Efficacy
-
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
-
Gilead (GILD) Says Biktarvy Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
-
Gilead Sciences (GILD) Announces U.S. FDA Approves Yescarta for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
-
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
-
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
-
Gilead Sciences (GILD) Completes Acquisition of MYR GmbH
-
Gilead Sciences Completes Acquisition of MYR GmbH
-
Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach
-
Gilead's (GILD) Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
-
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
-
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
-
Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend
-
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
-
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
-
Gilead (GILD) and Vir Biotechnology (VIR) Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
-
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
-
Pre-Open Stock Movers 01/11: (MESO) (LLY) (WBAI) Higher; (MARA) (RIOT) (MSTR) Lower (more...)
-
Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
-
Gilead's (GILD) Kite Tecartus Granted Conditional Marketing Authorization for Treatment of R/R Mantle Cell Lymphoma in Europe
-
Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
-
Gilead (GILD) Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy in Metastatic TNBC
-
Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer
-
Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States
-
Gilead Sciences (GILD) Announces Jeffrey A. Bluestone to Board
-
Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors
